- Home
- WSC vs NAMS Comparison
WSC vs NAMS Comparison
Compare WSC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | NAMS |
|---|---|---|
| Founded | 1944 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WSC | NAMS |
|---|---|---|
| Price | $21.08 | $33.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $25.71 | ★ $46.56 |
| AVG Volume (30 Days) | ★ 1.7M | 712.3K |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 816.06 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $2,317,990,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.46 |
| P/E Ratio | $17.60 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $14.91 | $14.06 |
| 52 Week High | $39.58 | $42.00 |
Technical Indicators
Market Signals| Indicator | WSC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 46.55 |
| Support Level | $20.91 | $30.17 |
| Resistance Level | $21.94 | $32.45 |
| Average True Range (ATR) | 0.84 | 1.74 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 50.48 | 47.41 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.